Angiodynamics (ANGO) Liabilities and Shareholders Equity (2016 - 2025)
Angiodynamics (ANGO) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $269.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $269.7 million, compared with a TTM value of $1.1 billion through Nov 2025, up 246.55%, and an annual FY2025 reading of $280.1 million, down 11.81% over the prior year.
- Liabilities and Shareholders Equity was $269.7 million for Q4 2025 at Angiodynamics, up from $265.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $582.2 million in Q1 2021 and bottomed at $265.6 million in Q3 2025.
- Average Liabilities and Shareholders Equity over 5 years is $467.8 million, with a median of $542.8 million recorded in 2023.
- The sharpest move saw Liabilities and Shareholders Equity rose 0.74% in 2022, then tumbled 40.36% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $554.1 million in 2021, then increased by 0.74% to $558.2 million in 2022, then fell by 10.5% to $499.6 million in 2023, then crashed by 36.41% to $317.7 million in 2024, then decreased by 15.11% to $269.7 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for ANGO at $269.7 million in Q4 2025, $265.6 million in Q3 2025, and $280.1 million in Q2 2025.